Cell3 Direct

June 14, 2021. Reviewed by Celina Whalley, April 26, 2024. Reducing the need for prophylactic anti-D treatment for pregnant women Non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cfDNA) in maternal plasma is being used to determine fetal RhD blood group antigen status so that RhD-negative pregnant women can avoid receiving antenatal anti-D if they…